We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is Editas Medicine (EDIT) Stock Outpacing Its Medical Peers This Year?
Read MoreHide Full Article
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Editas Medicine (EDIT - Free Report) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
Editas Medicine is one of 1001 individual stocks in the Medical sector. Collectively, these companies sit at #5 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.
The Zacks Rank is a proven model that highlights a variety of stocks with the right characteristics to outperform the market over the next one to three months. The system emphasizes earnings estimate revisions and favors companies with improving earnings outlooks. Editas Medicine is currently sporting a Zacks Rank of #2 (Buy).
Within the past quarter, the Zacks Consensus Estimate for EDIT's full-year earnings has moved 7.8% higher. This shows that analyst sentiment has improved and the company's earnings outlook is stronger.
Based on the latest available data, EDIT has gained about 21.3% so far this year. Meanwhile, stocks in the Medical group have lost about 4.2% on average. This means that Editas Medicine is performing better than its sector in terms of year-to-date returns.
Another Medical stock, which has outperformed the sector so far this year, is Arbutus Biopharma (ABUS - Free Report) . The stock has returned 2.5% year-to-date.
In Arbutus Biopharma's case, the consensus EPS estimate for the current year increased 42.7% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Breaking things down more, Editas Medicine is a member of the Medical - Biomedical and Genetics industry, which includes 508 individual companies and currently sits at #85 in the Zacks Industry Rank. On average, this group has lost an average of 6.4% so far this year, meaning that EDIT is performing better in terms of year-to-date returns. Arbutus Biopharma is also part of the same industry.
Investors interested in the Medical sector may want to keep a close eye on Editas Medicine and Arbutus Biopharma as they attempt to continue their solid performance.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Is Editas Medicine (EDIT) Stock Outpacing Its Medical Peers This Year?
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Editas Medicine (EDIT - Free Report) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
Editas Medicine is one of 1001 individual stocks in the Medical sector. Collectively, these companies sit at #5 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.
The Zacks Rank is a proven model that highlights a variety of stocks with the right characteristics to outperform the market over the next one to three months. The system emphasizes earnings estimate revisions and favors companies with improving earnings outlooks. Editas Medicine is currently sporting a Zacks Rank of #2 (Buy).
Within the past quarter, the Zacks Consensus Estimate for EDIT's full-year earnings has moved 7.8% higher. This shows that analyst sentiment has improved and the company's earnings outlook is stronger.
Based on the latest available data, EDIT has gained about 21.3% so far this year. Meanwhile, stocks in the Medical group have lost about 4.2% on average. This means that Editas Medicine is performing better than its sector in terms of year-to-date returns.
Another Medical stock, which has outperformed the sector so far this year, is Arbutus Biopharma (ABUS - Free Report) . The stock has returned 2.5% year-to-date.
In Arbutus Biopharma's case, the consensus EPS estimate for the current year increased 42.7% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Breaking things down more, Editas Medicine is a member of the Medical - Biomedical and Genetics industry, which includes 508 individual companies and currently sits at #85 in the Zacks Industry Rank. On average, this group has lost an average of 6.4% so far this year, meaning that EDIT is performing better in terms of year-to-date returns. Arbutus Biopharma is also part of the same industry.
Investors interested in the Medical sector may want to keep a close eye on Editas Medicine and Arbutus Biopharma as they attempt to continue their solid performance.